Damora Therapeutics (DMRA) Accumulated Expenses (2019 - 2026)

Damora Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• Quarterly Accumulated Expenses rose 401.0% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 401.0% YoY) and the FY2025 annual result came in at $2.4 million, up 192.8% from the prior year.
• Accumulated Expenses was $6.0 million for Q1 2026 at Damora Therapeutics, up from $2.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.5 million in Q1 2023 and bottomed at $820000.0 in Q4 2024.
• A 5-year average of $4.6 million and a median of $4.0 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses tumbled 80.14% — and 2026, when it soared 401.0%.
• Damora Therapeutics' Accumulated Expenses stood at $7.8 million in 2022, then sank by 46.78% to $4.1 million in 2023, then tumbled by 80.14% to $820000.0 in 2024, then surged by 192.8% to $2.4 million in 2025, then soared by 149.77% to $6.0 million in 2026.
• Business Quant data shows DMRA's Accumulated Expenses at $6.0 million in Q1 2026, $2.4 million in Q4 2025, and $2.1 million in Q3 2025.